ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer SAN FRANCISCO, May 01, 2018 (GLOBE NEWSWIRE) -- ViewPoint Therapeutics, Inc., a privately-held biotechnology company pioneering the development of crystallin stabilizers to prevent and treat...

ViewPoint Therapeutics Raises $35 Million in Series B Financing -- Proceeds will advance lead product candidate through clinical proof-of-concept studies in cataracts and presbyopia -- -- Series B led by The Rise Fund, a global impact fund -- SAN FRANCISCO,...

ViewPoint Therapeutics Raises $4 Million in Series A Financing -- Proceeds Will Advance Preclinical Crystallin Stabilizers for Treating and Preventing Cataracts and Presbyopia ---- Founders, Board and Scientific Advisors Bring World-Class Experience in Protein...